Evidence map›Paper›PMID 38501028›Full record

ArticleCureus2024

Clinicopathological Evaluation of Papillary Thyroid Microcarcinoma.

Ando Takahito, Kimihito Fujii, Hirona Banno, Masayuki Saito, Yukie Ito, Mirai Ido, Manami Goto, Yukako Mouri, Junko Kousaka, Tsuneo Imai and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ando TakahitoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Kimihito FujiiDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Hirona BannoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Masayuki SaitoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Yukie ItoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Mirai IdoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Manami GotoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Yukako MouriDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Junko KousakaDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Tsuneo ImaiDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Shogo NakanoDivision of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Nagakute, JPN.
Aichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsClinicians sometimes encounter papillary thyroid microcarcinoma (PMC) that is less than 10 mm, associated with lymph node metastasis. In this study, we assessed PMC clinicopathologically to clarify risk factors for poor prognosis. PATIENTS AND

methodsFifty-one patients who underwent thyroid surgery at Aichi Medical University from September 2009 to October 2016 were included. Patients were divided into two groups, pEX-positive (23 patients) and pEX-negative (28 patients), based on the pathological finding of thyroid capsule invasion. The former indicates that the tumor infiltrated the thyroid capsule and spread to the neighboring tissue, and the latter indicates no capsule invasion. We analyzed factors such as patient characteristics, pathological findings, and serum levels of thyroid hormones in the two groups.

resultsNo statistical differences were observed between the two groups in gender distribution or age at surgery. Preoperative cancer diagnoses were established for more patients in the pEX-positive group than in the pEX-negative group (n = 21 and 14, respectively; P = 0.004). The mean (±SD) pathological tumor diameter was 5.42 ± 2.77 in the pEX-negative group and 8.32 ± 1.61 in the pEX-positive group (P < 0.001). No significant differences in preoperative serum levels of free T3, free T4, thyroid-stimulating hormone, or thyroglobulin were observed between the two groups. The odds ratio for node positivity in tumors invading thyroid capsules (pEX-positive) compared to those with no capsule invasion (pEX-negative) was 13.20 (95% confidence interval, 3.45-50.42). Immunohistological staining for phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and Akt (protein kinase B) revealed the facilitation of PTEN and suppression of Akt, which might indicate downregulation of the phosphoinositide 3-kinase-Akt (PI3K-Akt) cascade. DISCUSSION: In general, the prognosis of PMC is favorable. However, the prognosis is less favorable in patients with nodal metastasis or extrathyroidal invasion. It is controversial whether resection is required for proven PMCs. For PMCs associated with extrathyroidal invasion, regional lymph node resection with lobectomy should be performed due to the high risk for lymphatic spread. There might be a possibility that the natural progression of PMC seems to be controlled by the facilitation of PTEN. However, a tumor in the lateral peripheral region of the thyroid parenchyma might be associated with capsule invasion followed by lymphatic spread.

Indexed as

extrathyroidal invasionlymph node metastasispapillary thyroid microcarcinomaptenthyroid capsule invasion

Identifiers

PMID38501028
PMCPMC10948234
OpenAlexW4392906521

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.